Fortive (NYSE:FTV) Stock, Quote.Headers.trade-ideas

Fortive

Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.1 billion in revenue in 2023.

xr:d:DAFhS-kD63I:2,j:45998648077,t:23042711

News

Intraday Update

Markets

Movers

Trading Ideas

ALGM

ALKS

ALLR

ATCH

ATPC

AZTR

BBLG

BLCO

CJET

CONN

CREV

DRMA

ENPH

FLEX

GERN

GOOGL

KARO

KORE

LITM

MANH

NAAS

NIVF

NUWE

NUZE

Next Technology Holding Inc. - Ordinary Shares

NXTT

PIRS

ROKU

SAGE

SGMO

SLNA

SOAR

SYNX

TKNO

TSLA

ULTA

VSTM

Vintage Wine Estates, Inc. - Common Stock

WFRD

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

FTV Logo

Earnings

Equities

Guidance

CZAR

Fortive reports Q2 FY24 results with revenue of $1.55B, slightly missing consensus. Adjusted EPS beats at $0.93. Lowered revenue outlook for FY24.

Fortive&#39;s Mixed Q2 Bag: Slight Revenue Miss Coupled with Tightened Full-Year Forecasts

Dominos Pizza in India

Upgrades

Analyst Ratings

GILD

SEDG

This Domino&#39;s Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Fortive Corp

Macro Economic Events

Economics

Federal Reserve

Fed's Kugler Says Fed Funds Rate Determines Policy; Balance Sheet Shrinking Is Not A Key Part Of Achieving Mandates; We Are Not Celebrating, We Are Not There Yet, On 2% Inflation Goal

Free Cash Flow before Growth (FCFbG) guidance increased to $1,975 million - $2,125 million from $1,825 - $2,075 million, representing a midpoint increase of $100 million.

NRG Energy Lifts FY24 Adjusted EBITDA Guidance From $3.30B - $3.55B To $3.525B - $3.675B

A leading player in psychoactive hemp-derived products (PHDs), LFTD Partners Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LIFD#OTC">LIFD</a>) is trading at just 0.2x CY24 EV/Sales, offering a steep discount. The stock has plummeted over 90% from its April 2021 peak but remains cash flow positive with a net cash position, leaving the company ripe for expansion through mergers and acquisitions. 
Despite regulatory pressures, LIFD's compliant strategy is expected to drive market share gains. According to a report from Zuanic &amp; Associates, the stock could see a 5x rise by December 2025.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Valuation And Growth Potential</h3>
LIFD trades at 0.2x CY24 EV/Sales, below its estimated liquidation value. <a href="https://www.benzinga.com/topic/pablo-zuanic">Zuanic&#8217;s report </a>suggests that if LIFD were to reach 0.5x sales on projected estimates, the stock could rise 5x by December 2025.&nbsp;
This makes the stock an attractive, albeit speculative, investment. The analyst assigns only a 10% probability to a scenario of a federal ban on PHDs, providing further support for the stock's upside potential. However, the future of LIFD is highly binary, driven by regulatory developments.
<h3 class="wp-block-heading">Regulatory Risks And Opportunities</h3>
LIFD's business has been heavily impacted by regulatory challenges at both the state and federal levels, with 19 states having banned <a href="https://www.benzinga.com/topic/hemp">PHDs</a> outright.&nbsp;
However, according to Zuanic, the upcoming<a href="https://www.benzinga.com/markets/cannabis/24/05/39006814/house-committee-approval-of-amendment-eliminating-90-of-hemp-dervied-products-could-drive-wedge-"> Farm Bill</a> is expected to delegate the regulation of PHDs to individual states, potentially allowing LIFD to capitalize on compliant strategies in states with strict regulations rather than outright bans.&nbsp;
This could lead to market share gains and top-line growth.
Zuanic notes that LIFD has the opportunity to benefit from collaboration with THC cannabis companies entering the PHD space, which could validate the compliant PHD market and lead to potential joint lobbying efforts.&nbsp;
The long-term regulatory convergence between PHDs and THC products is another potential upside.
Read Also:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/09/40906131/this-is-life-or-death-families-of-disabled-children-panic-over-gov-newsoms-hemp-cbd-ban-and-eval">&#8216;This Is Life Or Death&#8217;: Families Of Disabled Children Panic Over Gov. Newsom&#8217;s Hemp CBD Ban And Evaluate Lawsuit</a>
<h3 class="wp-block-heading">Bull Vs. Bear Case</h3>
In the bull case, if the regulatory landscape clarifies and no state bans emerge in key markets, LIFD's EV/Sales multiple could return to a 0.5-1.0x range.&nbsp;
This would imply a substantial upside. In the bear case, if federal legislation leads to a ban on PHDs or the company's nutraceutical strategy fails, the stock could face a total loss in value. However, Zuanic assigns just a 10% probability to this worst-case scenario.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">Gov. Newsom&#8217;s Hemp Ban Goes Into Effect: Consequences For Industry, Investors, Patients</a>

Biotech

Cannabis

Initiation

LIFD

LIFD's 5x Potential: Is This Psychoactive Hemp Stock The Next Big Speculative Buy?

QRTEA

Qurate Retail Entered Into Call Agreement With Gregory B. Maffei, Executive Chairman Of Co; Pursuant To Deal, Gregory B. Maffei Granted To Co Right To Purchase All Shares Of High Vote Stock Owned By Maffei Upon His Death

WIIM

Pagaya Technologies shares are trading lower after the company announced its intention to offer $125 million of exchangeable senior notes due 2029 in a private offering.

&nbsp;The initial Annual Meeting occurred on&nbsp;September 25, 2024, at&nbsp;9AM ET&nbsp;and did not meet quorate and thus was adjourned for one week. We encourage Bit Digital shareholders to vote on the proposals.

BTBT

Bit Digital Adjourns Annual General Meeting Until October 2, 2024

Fed's Kugler Says Policy Is Restrictive; With Disinflation, We Need To Cut Even Just Keep Where We Are In Terms Of Restrictiveness; We Have A Resilient Labor Market, We Don't Want Demand To Fall Further When It's Not Necessary; Makes Sense To Cut Rates To Remove Some Restrictiveness; We Are Way Above Any Estimates Of Neutral

The company&#39;s ordinary shares will continue to be listed on NASDAQ, and the CUSIP and ISIN will remain unchanged.

CACO

Caravelle Plans To Change Ticker Symbol From 'CACO' To 'HTCO' On September 30, 2024

IHOP&#xAE;, a leader in the family dining restaurant sector, today announced that Jay Johns will retire after 16 years at Dine Brands and nearly six years as President of IHOP. Johns will step down from his role on January 6, 2025, but will remain involved with the company in an advisory capacity until March 2025. Lawrence Kim, previously Chief Innovation Officer at YUM! Brands has been appointed President Designee effective October 21, 2024, and will assume title of IHOP President on January 6, 2025.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20240925469774/en/">https://www.businesswire.com/news/home/20240925469774/en/</a>
Since joining Dine in 2012, Johns has held various leadership roles focused on improving restaurant performance and operations. As the President of IHOP, Johns successfully navigated the challenges posed by the pandemic, helping IHOP adapt through increased off-premise dining, curbside pickup, and delivery services. He has also prioritized modernizing the brand through digital initiatives and technology, including launching its loyalty program, making IHOP more accessible to a tech-savvy guest base.

Management

IHOP Announces Leadership Transition, President Jay Johns To Retire On January 6, 2025; Lawrence Kim Appointed As Successor

Concentrix Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) reported its third-quarter financial results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/09/g41034257/concentrix-reports-third-quarter-2024-results">details from the report.&nbsp;</a>
The Details: Concentrix reported quarterly earnings of $2.87 per share, which missed the analyst consensus estimate of $2.93 by 2.05%. Quarterly revenue came in at $2.387 billion, which beat the analyst consensus estimate of $2.382 billion and represents a 46.2% increase over the same period last year.
The company reported operating income of $153.2 million, a reduction year-on-year primarily due to increased amortization of intangibles and planned integration expenses associated with the company&#8217;s combination with Webhelp, which closed in the fourth quarter of 2023.
Read Next: <a href="https://www.benzinga.com/news/24/09/41028294/whats-going-on-with-snowflake-stock">What&#8217;s Going On With Snowflake Stock?</a>
Concentrix also announced the launch of iX Hello, a generative AI-powered solution for organizations to boost productivity and engagement within an on-brand, secure environment. iX Hello marks the first product launch in a suite of AI and GenAI technologies which the company has already deployed internally and with pre-launch clients.
&#8220;Our third quarter marked another quarter of solid revenue growth and operating results,&#8221; said Chris Caldwell, president and CEO of Concentrix. 
&#8220;We are also delighted to leverage our technology investments to bring our iX Hello product to market with velocity. We believe iX Hello helps augment our existing technology partner strategies, underscores the positive transformation of our business and reflects our strong competitive position as the world&#8217;s most trusted provider of intelligent experience solutions.&#8221;
Outlook: Concentrix sees fourth-quarter revenue in a range of $2.42 billion to $2.47 billion and adjusted earnings of between $2.90 and $3.16 per share. The company sees fiscal year 2024 revenue in a range of $9.591 billion to $9.641 billion and adjusted earnings of between $11.05 and $11.31 per share. 
CNXC Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Concentrix shares are down 14.02% after-hours at $54.70 at the time of publication Wednesday.&nbsp;
Read Also: <a href="https://www.benzinga.com/news/24/09/41011763/whats-going-on-with-intel-stock"> </a> • <a href="https://www.benzinga.com/news/24/09/41011763/whats-going-on-with-intel-stock">What&#8217;s Going On With Intel Stock?</a>
Photo: Shutterstock

CNXC

Concentrix Stock Falls After Mixed Q3 Results, iX Hello GenAI Launch Annoucement

General

Pfizer Voluntarily Withdraws All Lots Of Its OXBRYTA Sickle Cell Disease Treatment From Worldwide Markets; Decision Based On The Totality Of Clinical Data That Now Indicates The Overall Benefit Of OXBRYTA No Longer Outweighs The Risk In The Approved Sickle Cell Patient Population

Offerings

Pagaya Technologies Intends To Offer $125M Of Exchangeable Senior Notes Due 2029 In Private Offering

Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) has outperformed the market over the past 20 years by 1.85% on an annualized basis producing an average annual return of 10.23%. Currently, Travelers Companies has a market capitalization of $53.86 billion. 
Buying $1000 In TRV: If an investor had bought $1000 of TRV stock 20 years ago, it would be worth $7,052.22 today based on a price of $236.32 for TRV at the time of writing.
<h3>Travelers Companies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727298016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Travelers Companies 20 Years Ago Would Be Worth Today

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 25.96% on an annualized basis producing an average annual return of 40.18%. Currently, Krystal Biotech has a market capitalization of $5.13 billion. 
Buying $1000 In KRYS: If an investor had bought $1000 of KRYS stock 5 years ago, it would be worth $5,170.05 today based on a price of $179.53 for KRYS at the time of writing.
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727298011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KRYS

$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today

For NBA star turned cannabis entrepreneur Al Harrington, the <a href="https://www.benzinga.com/markets/cannabis/24/09/41011619/it-takes-a-village-to-build-generational-wealth-nbas-al-harrington-on-his-full-circle-moment-and">opening of Village Dispensary in Hoboken</a>, New Jersey, represents much more than just business expansion. It&#8217;s part of a mission to rectify historical wrongs and empower the communities most affected by the <a href="https://drupal-cloudfront.benzinga.com/topic/war-on-drugs">War on Drugs</a>. Harrington's personal story and connection to the cannabis industry are intertwined with his desire to create generational wealth for marginalized communities.
Village Dispensary is part of Village Brands, Harrington's latest venture, and it brings a unique approach to the saturated cannabis market. With a philosophy rooted in community and empowerment, Harrington is determined to carve out a new path for the industry.
"When we were thinking about what to name the stores, we realized, Coca-Cola doesn't have Coca-Cola stores. And retailers might not like it if your brand is also the name of a dispensary,&#8221; Harrington explains in an exclusive interview with <a href="https://www.benzinga.com/cannabis">Benzinga Cannabis</a>. This was the inspiration behind the name &#8220;Village,&#8221; which reflects unity, growth and collective progress. "We've been bringing people together for the last 13 years through this magnificent opportunity to work with the cannabis plant, and it takes a village to do anything great," he adds.
&#x2A; This is part 2 of a 3-article series with Al Harrington. Check out part 1 <a href="https://www.benzinga.com/markets/cannabis/24/09/41011619/it-takes-a-village-to-build-generational-wealth-nbas-al-harrington-on-his-full-circle-moment-and">here</a> (<a href="https://www.benzinga.com/markets/cannabis/24/09/41011619/it-takes-a-village-to-build-generational-wealth-nbas-al-harrington-on-his-full-circle-moment-and">&#8216;It Takes A Village…To Build Generational Wealth&#8217;: NBA&#8217;s Al Harrington On His Full Circle Moment And Opening NJ Cannabis Dispensary</a>) and follow <a href="https://www.benzinga.com/cannabis">Benzinga Cannabis</a> to catch part 3.
<h3 class="wp-block-heading">Empowering Communities Hit By Prohibition</h3>
Village Dispensary's opening in Hoboken marks a key step in Harrington's larger plan to empower communities that have been disproportionately impacted by cannabis prohibition. The dispensary symbolizes progress and justice for people of color, especially those who have faced the harshest consequences of the drug war.
&#8220;This is a way for us to get generational wealth,&#8221; Harrington says, reflecting on the need to create opportunities for people of color to thrive in the cannabis space. His advocacy for inclusion goes far beyond typical business objectives, tapping into a desire for justice and fair representation in an industry that has long excluded those most affected by prohibition.
Harrington's passion for using the cannabis industry as a platform for change is personal, and it's evident in his approach to business. "We don't forget the people that were mostly harmed and negatively affected by it," he says. 
<h3 class="wp-block-heading">Experience, Education, Empowerment</h3>
At the core of Harrington's ethos for Village Dispensary is the belief that the business should offer more than just cannabis products—it should provide an experience built on education and empowerment. He's keenly aware that the cannabis consumer base has diversified, from novices to seasoned veterans. That's why the dispensary places a heavy emphasis on educating both customers and staff.
"We require all of our budtenders to do vendor days, where the brands come in and explain exactly who they are, the ethos of their company, how they started it, and then give background on all of their products," Harrington told Benzinga. This emphasis on knowledge-sharing goes beyond typical retail training. It's about ensuring that staff can provide informed guidance to customers. "They [the budtenders] can really have real conversations with the customers to make sure that they're getting what they're looking for and what they actually need.&#8221; 
Harrington understands that the cannabis space can be intimidating for new consumers, particularly older customers or those who are unfamiliar with it the new industry. Village Dispensary aims to break down those barriers. Harrington shares stories of customers who have rediscovered cannabis as a medicinal alternative after decades of abstaining.
&#8220;Some of them say, ‘I haven't smoked a joint in 30 or 40 years,' or, ‘I'm so happy that I can actually use this instead of taking these pills because it makes me feel this way compared to when I use this.'" Harrington recounted stories that highlight the impact cannabis can have as a medical alternative.
These stories reflect the shifting perception of cannabis, one that Harrington has been a part of shaping. He doesn't just see cannabis as a product to sell but rather as a tool to address problems people have faced for decades. And as more consumers discover the benefits of cannabis, Harrington is confident that the stigmas attached to it will continue to fade.
<h3 class="wp-block-heading">&#8216;Be Impactful First, Make Money Second&#8216;</h3>
While the Hoboken location is a significant milestone for Village Brands, it's just one piece of Harrington's broader vision. He&#8217;s already established a foothold on the West Coast with operations in California and Colorado and expanded to states like Illinois and Missouri. But New Jersey holds a special place in Harrington's heart, as it's where his journey with cannabis began.
&#8220;My grandmother is from Irvington. My other grandmother, they lived in East Orange. So I definitely have family and connection to a lot of different places in Jersey,&#8221; Harrington says. Opening a dispensary in his home state brings his career full circle, but he is far from finished.
Harrington is already looking toward expanding Village Brands into other states. New York, Virginia, Florida and Georgia are all on his radar. However, his expansion strategy goes beyond opening more stores. &#8220;The strategy is always to find something that can be impactful first and make money second," Harrington explains. 
Harrington's long-term vision for Village Brands is deeply rooted in empowerment, education, and creating lasting opportunities for communities that have been historically marginalized. As Village Dispensary continues to expand, Harrington remains committed to using his business as a vehicle for change, ensuring that the cannabis industry becomes more inclusive and accessible.
Photo courtesy of Village Brands

Retail Sales

Sports

Exclusives

Interview

NBA's Al Harrington: 'We Don't Forget Those Harmed By Cannabis Prohibition,' Our Mission Is Impact Before Profit

Fed's Kugler Says Below 100,000 Monthly Job Gain Would Be 'Very Low,' Must Be Mindful Of Potential Downward Revisions; Breakeven Number For Monthly Job Gains Is Anywhere From 100k To 240k

Jefferies Financial Q3 2024 Adj EPS $0.78, Inline

Telesis Bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares are soaring in extended trading Wednesday after the company announced a partnership to <a href="https://www.benzinga.com/pressreleases/24/09/g41034251/telesis-bio-and-beckman-coulter-life-sciences-collaborate-to-revolutionize-dna-and-mrna-synthesis">revolutionize DNA and mRNA synthesis</a>.
What Happened: Telesis Bio reached a new partnership with laboratory automation and innovation company Beckman Coulter Life Sciences to create efficient and scalable biofoundries and deliver solutions for DNA synthesis.
The partnership will integrate Telesis Bio&#8217;s Gibson SOLA Enzymatic Synthesis technology with Beckman Coulter&#8217;s new Biomek Echo One System, further expanding its flexibility to synthesize biology.
&#8220;This partnership marks a significant milestone in advancing synthetic biology. By integrating Gibson SOLA&#8217;s high-fidelity, scalable, and non-toxic DNA synthesis capabilities with Beckman Coulter Life Sciences automation expertise, we are setting a new standard for on-premises biofoundries,&#8221; said Eric Esser, CEO of Telesis Bio.
&#8220;This collaboration empowers researchers to greatly improve productivity through faster, more reliable and innovative solutions, driving forward the next generation of therapeutic and diagnostic advancements.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/24/09/41034733/micron-q4-earnings-revenue-eps-beat-on-robust-ai-demand-company-sees-significantly-improved-profita">Micron Q4 Earnings: Revenue, EPS Beat On &#8216;Robust AI Demand,&#8217; Company Sees &#8216;Significantly Improved&#8217; Profitability Ahead, Shares Surge</a>
Telesis Bio provides non-toxic, high-fidelity and scalable DNA synthesis, empowering scientists to create novel, synthetic biology-enabled solutions.
Telesis Bio is considered a low-float stock with approximately 406,000 shares available for public trading, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. It also had a market cap of less than $5 million as of Wednesday&#8217;s close. Low-float, micro-cap stocks often trade with elevated volatility, which may help explain some of Telesis Bio&#8217;s massive move after the bell.
TBIO Price Action: <a href="http://benzinga.com/quote/tbio">Telesis Bio shares</a> were up 110.02% at $4.87 in after-hours trading Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

Contracts

After-Hours Center

TBIO

Telesis Bio Stock Is Soaring Wednesday: What's Going On?

Micron CEO Says Demand From Data Center Customers Continues To Be Strong, And Customer Inventory Levels Are Healthy, Expect Healthier Inventories At PC OEMs By Spring 2025; Says Smartphone Unit Volumes On Track To Grow In The Low To Mid-Single-Digit Percentage Range In Calendar 2024

AMAT

ASML

AVGO

INTC

KLAC

LEDS

LRCX

LSCC

MCHP

MRVL

NVDA

NXPI

QCOM

RMBS

SIMO

TSEM

Shares of semiconductor and chip stocks are trading higher following strong earnings from Micron.

RBC Capital analyst Deane Dray maintained a Hold rating on Fortive (FTV – Research Report) yesterday and set a price target of $77.00. The company'...

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Fortive

Fortive (FTV) Forecast

Fortive (NYSE:FTV) Stock, Quote.Headers.trade-ideas